Skip Navigation
ChemIDplus Lite•Browse•Advanced

Substance Name: Olanzapine [USAN:USP:INN:BAN]
RN: 132539-06-1
UNII: N7U69T4SZR
InChIKey: KVWDHTXUZHCGIO-UHFFFAOYSA-N

Note

  • A benzodiazepine derivative that binds SEROTONIN RECEPTORS; MUSCARINIC RECEPTORS; HISTAMINE H1 RECEPTORS; ADRENERGIC ALPHA-1 RECEPTORS; and DOPAMINE RECEPTORS. It is an antipsychotic agent used in the treatment of SCHIZOPHRENIA; BIPOLAR DISORDER; and MAJOR DEPRESSIVE DISORDER; it may also reduce nausea and vomiting in patients undergoing chemotherapy.

Molecular Formula

  • C17-H20-N4-S

Molecular Weight

  • 312.439
 

Classification Codes

  • Antiemetics
  • Antipsychotic
  • Antipsychotic Agents
  • Autonomic Agents
  • Central Nervous System Agents
  • Central Nervous System Depressants
  • Gastrointestinal Agents
  • Membrane Transport Modulators
  • Neurotransmitter Agents
  • Neurotransmitter Uptake Inhibitors
  • Peripheral Nervous System Agents
  • Psychotropic Drugs
  • Serotonin Agents
  • Serotonin Uptake Inhibitors
  • Tranquilizing Agents

Names and Synonyms

Name of Substance

  • Olanzapine
  • Olanzapine [USAN:USP:INN:BAN]

MeSH Heading

  • Olanzapine

Synonyms

  • 2-Methyl-4-(4-methyl-1-piperazinyl)-10H-thieno(2,3-b)(1,5)benzodiazepine
  • HSDB 8155
  • LY 170053
  • LY-170053
  • LY170053
  • Olansek
  • Olanzapine
  • Olanzapine Teva
  • Olanzapine Mylan
  • Olanzapine Neopharma
  • UNII-N7U69T4SZR
  • Zalasta
  • Zypadhera
  • Zyprexa
  • Zyprexa Intramuscular
  • Zyprexa Velotab
  • Zyprexa Zydis

Systematic Name

  • 10H-Thieno(2,3-b)(1,5)benzodiazepine, 2-methyl-4-(4-methyl-1-piperazinyl)-

Mixture Name

  • Symbyax

Registry Numbers

CAS Registry Number

  • 132539-06-1

FDA UNII

  • N7U69T4SZR

System Generated Number

  • 0132539061

Structure Descriptors

InChI

InChI=1S/C17H20N4S/c1-12-11-13-16(21-9-7-20(2)8-10-21)18-14-5-3-4-6-15(14)19-17(13)22-12/h3-6,11,19H,7-10H2,1-2H3

InChIKey

KVWDHTXUZHCGIO-UHFFFAOYSA-N

Smiles

CN1CCN(CC1)C2=Nc3ccccc3Nc4sc(C)cc24

Toxicity

Organism Test Type Route Reported Dose (Normalized Dose) Effect Source
human TDLo oral 16560ug/kg/12 (16.56mg/kg)   Journal of Clinical Psychiatry. Vol. 60, Pg. 767, 1999.
human TDLo oral 16560ug/kg/12 (16.56mg/kg) BLOOD: "CHANGES IN SERUM COMPOSITION (E.G., TP, BILIRUBIN, CHOLESTEROL)" Journal of Clinical Psychiatry. Vol. 60, Pg. 767, 1999.
human TDLo oral 43mg/kg/30W-I (43mg/kg)   Journal of Clinical Pyschopharmacology. Vol. 19, Pg. 273, 1999.
man LDLo oral 7067ug/kg (7.067mg/kg) LUNGS, THORAX, OR RESPIRATION: ACUTE PULMONARY EDEMA

GASTROINTESTINAL: NAUSEA OR VOMITING

LIVER: "HEPATITIS, FIBROUS (CIRRHOSIS, POST-NECROTIC SCARRING)"		 Journal of Forensic Sciences. Vol. 41, Pg. 1252, 1998.
man TDLo oral 2570ug/kg/12D (2.57mg/kg) AUTONOMIC NERVOUS SYSTEM: OTHER (DIRECT) PARASYMPATHOMIMETIC Journal of Clinical Pyschopharmacology. Vol. 19, Pg. 192, 1999.
women LDLo oral 30mg/kg/22W-I (30mg/kg) VASCULAR: BP LOWERING NOT CHARACTERIZED IN AUTONOMIC SECTION

BEHAVIORAL: CONVULSIONS OR EFFECT ON SEIZURE THRESHOLD		 Annals of Pharmacotherpy. Vol. 33, Pg. 787, 1999.
women TDLo oral 400ug/kg (0.4mg/kg)   American Journal of Psychiatry. Vol. 156, Pg. 1835, 1999.
women TDLo oral 400ug/kg (0.4mg/kg) VASCULAR: BP ELEVATION NOT CHARACTERIZED IN AUTONOMIC SECTION

BEHAVIORAL: REGIDITY		 American Journal of Psychiatry. Vol. 156, Pg. 1835, 1999.
women TDLo oral 12mg/kg (12mg/kg) BEHAVIORAL: COMA

CARDIAC: PULSE RATE INCREASE WITHOUT FALL IN BP

CARDIAC: EKG CHANGES NOT DIAGNOSTIC OF ABOVE		 Annals of Emergency Medicine. Vol. 32, Pg. 275, 1998.
women TDLo oral 12mg/kg/60D-I (12mg/kg) BEHAVIORAL: TOXIC PSYCHOSIS Annals of Internal Medicine. Vol. 131, Pg. 72, 1999.